´ëÇѽŰæ¸é¿ªÇÐȸ 2023³â ÇÏ°èÇмú´ëȸ : 2023-08-12
±³À°ÀÏÀÚ : 2023-08-12
±³À°Àå¼Ò : º¸ÄÚ°³²¼¿ï LLÃþ(B2) º¼·ë (¿ÀÇÁ¶óÀÎ °³ÃÖ)
±³À°ÁÖÁ¦ : ´ëÇѽŰæ¸é¿ªÇÐȸ 2023³â ÇÏ°èÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇѽŰæ°úÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѽŰæ¸é¿ªÇÐȸ
´ã´çÀÚ : ´ëÇѽŰæ¸é¿ªÇÐȸ »ç¹«±¹
¿¬¶ôó : 02-720-1594
À̸ÞÀÏ : ksms1594@daum.net
±³À°Á¾·ù : ½Å°æ°ú
Âü¼®¿¹»óÀÎ : 80¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 5ºÐ
¼¼ºÎ¼ö°·á : 90,000¿ø
ºñ°í »çÀüµî·Ï: Àü°øÀÇ(ȸ¿ø) 2¸¸¿ø, Àü¹®ÀÇ,±âŸ(ȸ¿ø) 4¸¸¿ø, ºñȸ¿ø 8¸¸¿ø / ´çÀϵî·Ï: Àü°øÀÇ(ȸ¿ø) 3¸¸¿ø, Àü¹®ÀÇ,±âŸ(ȸ¿ø) 5¸¸¿ø, ºñȸ¿ø 9¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08¿ù 12ÀÏ º¸ÄÚ°³²¼¿ï LLÃþ(B2) º¼·ë 09:10~09:35 Multiple Sclerosis (MS) ¹ÚÁø¿ì(°í·ÁÀÇ´ë ½Å°æ°ú)
±³À°½Ã°£ 08¿ù 12ÀÏ º¸ÄÚ°³²¼¿ï LLÃþ(B2) º¼·ë 09:35~10:00 Neuromyelitis Optica Spectrum Disorder(NMOSD) & Myelin oligodendrocyte glycoprotein antibody-associated disease(MOGAD) ±è±âÈÆ(±¹¸³¾Ï¼¾ÅÍ ½Å°æ°ú)
±³À°½Ã°£ 08¿ù 12ÀÏ º¸ÄÚ°³²¼¿ï LLÃþ(B2) º¼·ë 10:00~10:20 Autoimmune encephalitis (AE) ÀåÀ±Çõ(¼¿ïÀÇ´ë ½Å°æ°ú)
Åä·Ð 08¿ù 12ÀÏ º¸ÄÚ°³²¼¿ï LLÃþ(B2) º¼·ë 10:20~10:30 Q&A ( )
±³À°½Ã°£ 08¿ù 12ÀÏ º¸ÄÚ°³²¼¿ï LLÃþ(B2) º¼·ë 10:45~11:05 Infection as a trigger factor of Multiple Sclerosis (MS) ÀÌÀºÀç(¿ï»êÀÇ´ë ½Å°æ°ú)
±³À°½Ã°£ 08¿ù 12ÀÏ º¸ÄÚ°³²¼¿ï LLÃþ(B2) º¼·ë 11:05~11:25 Vitamin D deficiency and supplementation in Multiple Sclerosis (MS) ¹ÎÁÖÈ«(¼º±Õ°üÀÇ´ë ½Å°æ°ú)
±³À°½Ã°£ 08¿ù 12ÀÏ º¸ÄÚ°³²¼¿ï LLÃþ(B2) º¼·ë 11:25~11:45 Diet and exercise ±èÁؼø(¼¿ïÀÇ´ë ½Å°æ°ú)
Åä·Ð 08¿ù 12ÀÏ º¸ÄÚ°³²¼¿ï LLÃþ(B2) º¼·ë 11:45~11:55 Q&A ( )
±³À°½Ã°£ 08¿ù 12ÀÏ º¸ÄÚ°³²¼¿ï LLÃþ(B2) º¼·ë 11:55~12:35 Tolerogenic Nanovaccine for Multiple Sclerosis ±èÀçÀ±(¼º±Õ°ü´ë ÈÇаøÇаú)
±³À°½Ã°£ 08¿ù 12ÀÏ º¸ÄÚ°³²¼¿ï LLÃþ(B2) º¼·ë 13:20~13:50 Scientific session ¥°(Neuroimmunology & Multiple Sclerosis (MS)) ¹ÎÁÖÈ«(¼º±Õ°üÀÇ´ë ½Å°æ°ú)
±³À°½Ã°£ 08¿ù 12ÀÏ º¸ÄÚ°³²¼¿ï LLÃþ(B2) º¼·ë 13:50~14:20 Tolerogenic Nanovaccine for Multiple Sclerosis ±è¼º¹Î(¼¿ïÀÇ´ë ½Å°æ°ú)
±³À°½Ã°£ 08¿ù 12ÀÏ º¸ÄÚ°³²¼¿ï LLÃþ(B2) º¼·ë 14:20~15:05 Scientific session ¥± (Neuroimmunology & Multiple Sclerosis (MS)) ±è¼öÇö ¼®Èï¿(±¹¸³¾Ï¼¾ÅÍ °è¸íÀÇ´ë)
±³À°½Ã°£ 08¿ù 12ÀÏ º¸ÄÚ°³²¼¿ï LLÃþ(B2) º¼·ë 15:20~15:40 Progression Independent of Relapse Activity in Relapsing-remitting multiple sclerosis ±Ç¿µ³²(¿¬¼¼ÀÇ´ë ½Å°æ°ú)
±³À°½Ã°£ 08¿ù 12ÀÏ º¸ÄÚ°³²¼¿ï LLÃþ(B2) º¼·ë 15:40~16:00 Diagnosis of Progressive multiple sclerosis ÇöÀç¿ø(±¹¸³¾Ï¼¾ÅÍ ½Å°æ°ú)
±³À°½Ã°£ 08¿ù 12ÀÏ º¸ÄÚ°³²¼¿ï LLÃþ(B2) º¼·ë 16:00~16:20 Treatments in Progressive multiple sclerosis ±è¿ìÁØ(°¡Å縯ÀÇ´ë ½Å°æ°ú)
Åä·Ð 08¿ù 12ÀÏ º¸ÄÚ°³²¼¿ï LLÃþ(B2) º¼·ë 16:20~16:30 Q&A ( )